Genfit and Ipsen announce elafibranor results
ELATIVE, a randomised PBC trial involving 161 patients, has successfully met its primary endpoint
Read More
Tag: Genfit
End of the line for Genfit’s experimental NASH drug
Development of elafibranor will be discontinued for NASH, with the company now focusing on its future as a treatment for PBC
Read More
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
